CHEMOTHERAPY VERSUS BEST SUPPORTIVE CARE IN STAGE IV NON-SMALL CELL LUNG CANCER, NON METASTATIC TO THE BRAIN

Agnaldo Anelli, Candice A. A. Lima, Riad N. Younes, Jefferson L. Gross and Ricardo Fogarolli

Stage IV non-small cell lung cancer is a fatal disease, with a median survival of 14 months. Systemic chemotherapy is the most common approach. However the impact in overall survival and quality of life still a controversy.

Objectives: To determine differences in overall survival and quality of life among patients with stage IV non-small cell lung cancer non-metastatic to the brain treated with best supportive care versus systemic chemotherapy.

Patients: From February 1990 through December 1995, 78 eligible patients were admitted with the diagnosis of stage IV non-small cell lung cancer. Patients were divided in 2 groups: Group A (n=31 – treated with best supportive care), and Group B (n=47 – treated with systemic chemotherapy).

Results: The median survival time was 23 weeks (range 5 – 153 weeks) in Group A and 55 weeks (range 7.4 – 213 weeks) in Group B (p=0.0018). In both groups, the incidence of admission for IV antibiotics and need of blood transfusions were similar. Patients receiving systemic chemotherapy were also stratified into those receiving mytomycin, vinblastin, and cisplatinum, n=25 and those receiving other combination regimens (platinum derivatives associated with other drugs, n=22). Patients receiving mytomycin, vinblastin, and cisplatinum, n=25 had a higher incidence of febrile neutropenia and had their cycles delayed for longer periods of time than the other group. These patients also had a shorter median survival time (51 versus 66 weeks, p=0.005).

Conclusion: In patients with stage IV non-small cell lung cancer, non-metastatic to the brain, chemotherapy significantly increases survival compared with best supportive care.


Non-small cell lung carcinoma (NSCLC) is a common tumor, with approximately half a million new cases registered every year worldwide. Thirty to 40% of all newly admitted patients present with disseminated metastatic disease with a limited or palliative role for localized surgical or radiation therapy. For patients with this advanced stage, chemotherapy (CT) is the treatment of choice in most centers.

Response rates with most regimens of chemotherapy range between 20% and 30%. Recently, the introduction of new agents, such as vinorelbine or the combination of cisplatinum or cisplatinum derivatives with paclitaxel, has resulted in higher response rates, reaching 60% in some series.

Those patients usually present a median survival of 6 months. The impact of chemotherapy on overall survival and quality of life of patients with metastatic NSCLC, as opposed to best supportive care solely, is still widely debated. Several studies have been published showing a small, although statistically significant, survival advantage for patients treated with chemotherapy. Meta-analyses and randomized studies have demonstrated a clear benefit following systemic treatment, with one of them reaching a survival advantage of 15 weeks. A subsequent study by the same center showed reduced overall medical costs for patients receiving chemotherapy, mainly when less expen-
sive regimens were administered\textsuperscript{15}. Other studies, however, did not report any advantageous trend for chemotherapy\textsuperscript{2}.

The present study evaluates clinical outcomes of patients with stage IV NSCLC, as well as the impact of different treatment modalities.

**PATIENTS AND METHODS**

A retrospective analysis was performed using a prospective database. To obtain a minimum follow-up of 5 years, the records were reviewed from February 1990 to December 1995, with histologically proven stage IV NSCLC and with no demonstrable central nervous system metastases on CT scan. The treatment modality of each individual patient was identified and registered (chemotherapy or best supportive care), as was the clinical outcome.

Study targets were defined as:

1. Survival analysis for both groups.
2. Assessment of quality of life, according to the following criteria: days of in hospital treatment, days of intravenously administered antibiotics, necessity for blood and blood derivative transfusion, and number of febrile neutropenia episodes.

Eighty-six consecutive patients were admitted during that period, with 8 patients being excluded from the final analysis due to loss of follow-up greater than 3 weeks after admission.

Survival time was calculated from the date of diagnosis. Logistic regression was used to adjust for and determine the significance of the effect of prognostic factors in the treatment comparison of response. Cox’s proportional hazard model was used to adjust for and determine the significance of the effect of prognostic factors in the treatment comparisons of time to event analyses (survival). All significance levels were two sided\textsuperscript{16}.

**RESULTS**

Thirty-one patients were treated with best supportive care - BSC (Group A), while 47 patients received chemotherapy and best supportive care - CT (Group B). Patient characteristics of the two groups are displayed in table 1.

BSC was defined as treatment of pain, cough, dyspnea, palliative radiotherapy, infections, and pleural effusions.

Both groups were comparable for age and sex. On the other hand, performance status was significantly lower in patients of Group A, with 26% of patients presenting with important health problems, compared to 4% in Group B. Patients in Group A more often underwent palliative radiotherapy (n=17 – 54.8%), than patients of Group B (n=26, 55.3%), although the difference was not significant.

Histology was significantly different between groups: Squamous cell carcinoma was more frequently diagnosed in Group A, while adenocarcinoma was the most frequent histology in Group B.

Chemotherapy was not indicated in patients of Group A for the following reasons:

1. Palliative radiotherapy (n=9).
2. Patient’s decision (n=5).
3. Medical decision to observe asymptomatic patients with ECOG performance status of 3 and 4 (n=8).
4. Infection on admission (n=1).
5. Immediate necessity for palliation (n=5) until significant symptoms.
6. Limiting comorbidity (cardiac failure, n=1, renal failure, n=2).

Median survival for Group A was 23 weeks, significantly lower than the 55 weeks for Group B (p=0.0018). Figure 1 shows the overall survival curve for all patients. Figure 2 shows survival according to modality of treatment.

Patients that received chemotherapy intended to treat metastatic disease were further divided into 2 subgroups, depending on the regimen used: MVP (mitomycin, vinblastin, and cisplatinum, n=25) considered the standard treatment in the institution at that period, or other investigational chemotherapy regimens (including cisplatinum derivatives in combination with etoposide or paclitaxel, and the combination of ifosfamide, cisplatinum, and vinblastin, n=22). Patients that received MVP had a 51-week median survival, significantly lower than the 66 weeks for the other group. Figure 3 shows the survival

**Table 1 - Patient characteristics.**

<table>
<thead>
<tr>
<th></th>
<th>Best Supportive Care n = 31</th>
<th>Chemotherapy n = 47</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td>Median 62 years</td>
<td>Median 57 years</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td>Male - 22 (71%) Female - 9 (29%)</td>
<td>Male - 32 (68%) Female - 15 (32%)</td>
</tr>
<tr>
<td><strong>Performance Status</strong></td>
<td>3 and 4 - 8 (26%)</td>
<td>3 and 4 - 2 (4%)</td>
</tr>
<tr>
<td><strong>Chest Radiotherapy</strong></td>
<td>17 (54.8%)</td>
<td>26 (55.3%)</td>
</tr>
<tr>
<td><strong>Squamous Cell</strong></td>
<td>15 (48%)</td>
<td>11 (23%)</td>
</tr>
<tr>
<td><strong>Adenocarcinoma</strong></td>
<td>8 (26%)</td>
<td>30 (64%)</td>
</tr>
<tr>
<td><strong>Others†</strong></td>
<td>8 (26%)</td>
<td>6 (12%)</td>
</tr>
</tbody>
</table>

*ECOG Performance Status; † Others defined as: Large Cell Carcinoma and Undifferentiated Carcinoma.
curves according to the chemotherapy regimen.

The overall response rate for chemotherapy was 19.1%, with no complete response: nine patients had a partial objective response (19.1%), 21 patients (44.7%) had stable disease, and 17 patients (36.2%) had progressive disease. Figure 4 shows survival curves for patients according to type of response.

Performance status on admission rendered the two groups too heterogeneous for a meaningful evaluation. However, when patients with ECOG PS 3-4 were excluded from both groups, survival was still significantly greater for patients treated with chemotherapy (51.2 weeks), compared to the other group (33.8 weeks), p=0.002.

Patients in Group A had a median in-hospital treatment time of 13 days, similar to 16.5 days in Group B. No significant differences were observed for antibiotic administration and transfusion episodes. Table 2 displays the corresponding data.

Episodes of neutropenia occurred exclusively in MVP patients (n=3 cycles). This chemotherapeutic regimen was associated with significant delays between cycles due to significant toxicity.

DISCUSSION

For patients with non-small cell lung cancer (NSCLC), the prospect of long-term survival is directly related to the surgical resectability of the primary tumor. At initial presentation, the great majority of NSCLC have either locally advanced inoperable disease, stage IV metastatic disease, or comorbid medical conditions that render them unsuitable for surgical intervention. Because of that, the vast majority of patients with NSCLC are candidates for systemic treatment with or without radiotherapy. A large number of clinical trials exploring combination chemotherapy in NSCLC have been per-
Several conclusions can be drawn from a review of phase II and phase III randomized trials performed in NSCLC patients15,17,18: (1) overall response rates usually range from 20% to 30%; (2) complete responses are an exception; (3) the majority of trials are based on the combination of a cisplatinum derivative and other drugs; (4) the overall impact of combination chemotherapy regimens on improved survival is modest; (5) the majority of patients rarely survive longer than 18 months, and most combination chemotherapy regimens are associated with some type of toxicity (mainly nausea, vomiting, and febrile neutropenia).

Although most of the trials of chemotherapy in NSCLC show only a marginal improvement in median length of survival, the majority do show a trend toward improved overall survival when compared with best supportive care (BSC). In a prospective randomized trial conducted by Italian investigators12, 102 patients with NSCLC were randomized to receive a combination of cisplatin, cyclophosphamide, and vinblastin or to receive BSC. In the group of patients receiving chemotherapy, the median overall survival was 8.5 months versus 4.0 months in the group receiving BSC (p<.0001).

In another randomized trial conducted by the National Cancer Institute of Canada13, patients were randomized to receive two different chemotherapy regimens (vindesin and cisplatin or cyclophosphamide, doxorubicin, and cisplatin) or BSC. Patients on the chemotherapy arms had a median overall survival of 32.6 and 24.7 weeks respectively versus 17 weeks for the group treated with BSC (p=0.05).

However, in two other studies, including a large randomized trial involving 188 patients, no statistically significant difference in survival was observed, although an advantage for chemotherapy was observed in some patients subsets17,18.
In our study, the median survival for patients receiving BSC was 23 weeks, significantly lower than 55 weeks for the group receiving chemotherapy (p=0.002). Our data shows that even when patients with a low ECOG performance status are excluded from analysis, overall survival is still higher in patients treated with chemotherapy compared to patients treated with best supportive care only.

Whether the gains in life expectancy are worth potential losses in quality of life from treatment side effects is largely an individual patients choice. The major challenge for oncologists would be to identify and develop properly designed instruments to collect information on how much the expected benefit is valued by the patients and to involve patients in the decision of treatment options, reflecting their own preferences.

**RESUMO**


O câncer de pulmão de células não pequenas em estádio IV é uma doença fatal, com uma sobrevida mediana de seis meses. Quimioterapia é a abordagem mais freqüente, apresentando um impacto na sobrevida controverso e questionável alteração na qualidade de vida.

**Objetivos:** Comparar o impacto na sobrevida global e na qualidade de vida em pacientes portadores de câncer de pulmão de células não pequenas, estádio IV, tratados com suporte clínico ou quimioterapia.

**Pacientes:** Entre fevereiro de 1990 e dezembro de 1995, 78 pacientes (pts) portadores de câncer de pulmão de células não pequenas estádio IV foram admitidos. Os pacientes foram divididos em dois grupos: grupo A (n=31 – tratados com suporte clínico) e grupo B (n=47, tratados com quimioterapia).

**Resultados:** A sobrevida mediana no grupo tratado com suporte clínico foi de 23 semanas (variando de 5-153 semanas) e de 55 semanas no grupo tratado com quimioterapia (variando de 7,4 a 213 semanas), p= 0,0018 – Qui-quadrado. Em ambos grupos, a incidência de internações hospitalares para a administração intravenosa de antibióticos e hemoderivados foi similar. Pacientes recebendo quimioterapia, foram estratificados entre aqueles que receberam mitomicina, vinblastina e cisplatina, n=25 e aqueles recebendo outros regimes (derivados de platina, associados à outras drogas, n= 22). Pacientes recebendo mitomicina, vinblastina e cisplatina, n=25 apresentaram uma incidência mais alta de neutropenia febril e tiveram atrasos mais longos entre os ciclos de quimioterapia, quando comparados aos pacientes do outro grupo. Pacientes recebendo mitomicina, vinblastina e cisplatina, n=25, também apresentaram uma pior sobrevida mediana (51 versus 66 semanas, p= 0.005 – Qui-quadrado).

**Conclusões:** Em pacientes com câncer de pulmão de células não pequenas, estádio IV, não metastático para os pulmões, o uso de quimioterapia aumenta a sobrevida de maneira estatisticamente significativa, quando comparado aos cuidados de suporte.

**DESCRITORES:** Quimioterapia. Câncer de pulmão de células não pequenas. Suporte clínico. Metomicicina, vinblastina e cisplatina. Doença fatal.
REFERENCES


Received for publication on October 27, 2000.